Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Appl Thromb Hemost ; 16(6): 614-21, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-20460350

RESUMO

International normalized ratio (INR) is used to monitor chronic oral anticoagulant (OA) treatment; however, it is poorly understood how this simple test reflects in vivo hemostatic reactions, culminating in thrombin generation and clot formation. We studied the process of thrombin generation using an ex vivo model, where thrombin-antithrombin (TAT) complexes are measured in blood emerging from standardized skin incisions in 55 patients (35 with venous thromboembolism [VTE] and 20 with sustained atrial fibrillation [AF]) treated with acenocoumarol (INR 2.0-3.0). In addition, in venous blood, we measured the activity of factor VIII (FVIII) and vitamin K-dependent coagulation proteins. Chronic anticoagulation led to significant reductions in maximum TAT concentrations as compared to 35 healthy controls, in maximum TAT generation rates, and in mean amount of thrombin generated. Parameters of thrombin generation did not correlate with INR or any coagulation factor measured. International normalized ratio was significantly and independently affected by the decrease in the activity of all vitamin K-dependent coagulation proteins. The strongest influence was shown for FVII. Factor VIII activity was increased in all patients studied independently of the duration of anticoagulation and did not change over time. In conclusion, in patients with VTE and AF on OA, there is no correlation between INR values and parameters of ex vivo thrombin generation. This may indicate an important role of protein C (PC) system and possibly other endothelium-dependent mechanisms in controlling hemostasis. Increased FVIII activity in patients with VTE and AF does not change significantly during anticoagulation and is probably related to the pretreatment prothrombotic state.


Assuntos
Acenocumarol/administração & dosagem , Anticoagulantes/administração & dosagem , Fibrilação Atrial/sangue , Fibrilação Atrial/tratamento farmacológico , Trombina/metabolismo , Tromboembolia Venosa/sangue , Tromboembolia Venosa/tratamento farmacológico , Antitrombinas/metabolismo , Estudos de Casos e Controles , Fator VIII/metabolismo , Feminino , Humanos , Coeficiente Internacional Normatizado , Assistência de Longa Duração , Masculino , Pessoa de Meia-Idade , Protrombina/metabolismo
2.
J Thromb Haemost ; 3(9): 2015-21, 2005 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16102108

RESUMO

Fibrin (Fn) cross-linking by activated factor (F) XIII is essential for clot stability. In vitro, a common Leu34 polymorphism of the FXIIIA-subunit increases the rate of thrombin-mediated FXIII activation, but not cross-linking activity upon complete FXIII activation. The effect of FXIII Val34Leu polymorphism on fibrin(ogen) cross-linking in vivo when vascular injury triggers the blood coagulation has not been studied yet. Using quantitative immunoblotting with antibodies raised against FXIIIA-subunits, fibrinogen, and gamma-gamma-dimers, the rates of FXIIIA cleavage and fibrin(ogen) cross-link formation in the fluid phase of 30-s blood samples collected at the site of microvascular injury were compared in the Leu34-positive and -negative healthy individuals and patients on long-term oral anticoagulation. In addition to accelerated FXIII activation, in healthy subjects the presence of FXIII Leu34 allele was associated with increased soluble gamma-gamma-dimer formation by 40% (1355 +/- 17 microg L(-1) for Leu34 carriers vs. 804.3 +/- 17 microg L(-1) for Leu34 non-carriers; P = 0.028) at the site of microvascular injury. This solution phase effect was abolished in coumadin-treated patients (369.4 +/- 75.9 microg L(-1) for Leu34 carriers vs. 290.5 +/- 35.9 microg L(-1) for Leu34 non-carriers; P > 0.05). The present study indicates that the Leu34 allele affects soluble gamma-gamma-dimer formation in untreated individuals, but not in those receiving acenocoumarol. Our data may help elucidate the impact of the FXIII Val34Leu polymorphism on Fn cross-linking in vivo and its modulation by oral anticoagulants.


Assuntos
Fator XIII/genética , Microcirculação/lesões , Mutação de Sentido Incorreto , Varfarina/farmacologia , Adulto , Anticoagulantes/farmacologia , Anticoagulantes/uso terapêutico , Fator XIII/metabolismo , Feminino , Fibrina/metabolismo , Heterozigoto , Homozigoto , Humanos , Masculino , Pessoa de Meia-Idade , Polimorfismo Genético , Subunidades Proteicas/metabolismo , Varfarina/uso terapêutico
3.
Pol Arch Med Wewn ; 105(3): 231-4, 2001 Mar.
Artigo em Polonês | MEDLINE | ID: mdl-11680268

RESUMO

A 57-year--woman with Reynolds syndrome (primary biliary cirrhosis and scleroderma) is reported. Diagnosis of primary biliary cirrhosis is based on clinical findings, laboratory tests results and histological result of liver biopsy. Scleroderma was confirmed by anticentromere antibodies presence, and typical skin lesions. Although, antimitochondrial antibodies are very typical for PBC (primary biliary cirrhosis), in this case the were not found.


Assuntos
Cirrose Hepática Biliar/complicações , Cirrose Hepática Biliar/imunologia , Escleroderma Sistêmico/complicações , Escleroderma Sistêmico/imunologia , Anticorpos/imunologia , Centrômero/imunologia , Feminino , Humanos , Pessoa de Meia-Idade , Síndrome
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...